


Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/552,065
				Filing Date	October 5, 2005
				First Named Inventor	Kai SCHIEMANN et al.
				Group Art Unit	1614
				Examiner Name	Christopher R. Stone
Sheet	1	of	4	Attorney Docket Number	MERCK-3074

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	2007/0093492		Jiaang et al.	04-2007
	A2	2006/0276650		Schadt et al.	12-2006
	A3	2007/0105871		Schiemann et al.	05-2007
	A4	2001/0044445		Bamaung et al.	11-2001
	A5	7,067,507		Pulley et al.	06-2006
	A6	4,631,343		Beck, James R.	12-1986
	A7	2004/0034083		Stephenson et al.	2-19-2004
	A8	2002/0091116		Zhu et al.	07-2002
	A9	2007/0010531		Schadt et al.	01-2007
	A10	6,150,393	A	Behan et al.	11-21-2000
	A11	6,043,261	A	Hansen Jr. et al.	03-28-2000
	A12	4,146,721	A	BYK GULDEN LOMBERG	03-27-1979
	A13	3,926,999		Poetsch	12-16-1975
	A14	4,258,047		Gante et al.	03-24-1981

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	0132626		Gaster Laramie Mary	05-10-2001		
	B2	WO	2001032627		Baron et al.	10-2001		
	B3	WO	03088958		Maziasz Timothy J	10-30-2003		
	B4	WO	98031227		Schiemann et al.	07-1998		
	B5	WO	2003031435		Schiemann et al.	04-17-2003		

Examiner Signature	/Christopher Stone/	Date Considered	05/27/2009
-----------------------	---------------------	--------------------	------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;"><i>(use as many sheets as necessary)</i></p>				Complete if Known	
		Application Number	10/552,065		
		Filing Date	October 5, 2005		
		First Named Inventor	Kai SCHIEMANN et al.		
		Group Art Unit	1614		
		Examiner Name	Christopher R. Stone		
		Attorney Docket Number	MERCK-3074		
Sheet	2	of	4		

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B6	WO	01/29008	A	ARENA PHARMACEUTICALS INC.	04-26-2001		A11
	B7	WO	96/33175	A	SEARLE & CO	10-24-1996		A12
	B8	DE	2141125	A	BYK-GULDEN LOMBERG GMBH	02-24-1972		
	B9	WO	03/099793	A	TAKEDA LTD	12-04-2003		
	B10	WO	2004/024705	A	TAKEDA LTD.	03-25-2004		
	B11	WO	2004/037248	A	CAREX SA	05-06-2004		
	B12	DE	2201889		Merck Patent GmbH	07-19-1973		A13
	B13	DE	2258033		Merck Patent GmbH	05-30-1974		
	B14	DE	2906252		Merck Patent GmbH	08-28-1980		A14

Examiner Signature	/Christopher Stone/	Date Considered	05/27/2009
-----------------------	---------------------	--------------------	------------

⁷ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

urden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/552,065
				Filing Date	October 5, 2005
				First Named Inventor	Kai SCHIEMANN et al.
				Group Art Unit	1614
				Examiner Name	Christopher R. Stone
				Attorney Docket Number	MERCK-3074
Sheet	3	of	4		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	DATABASE BEILSTEIN 'ONLINE' BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, JUNE 27, 1988, XP002283830.	
	C2	Vippagunta et al. Advanced Drug Delivery Reviews, 2001, 48, 3-26.	
	C3	"Premenstrual syndrome-Womens health and Medical Information in Medicinenet.com", http://www.medicinenet.com/premenstrual_syndrome/page5.htm , accessed September 19, 2007.	
	C4	"Amyotrophic Lateral sclerosis information page: National Institute of Neurological Disorders and Stroke (NINDS)", http://www.ninds.gov/disorders/amyotrophiclateralsclerosis/amyotrophiclateralsclerosis.htm , accessed September 19, 2007.	
	C5	"Obsessive-compulsive behaviors and disorders: symptoms, treatment, and support", http://www.helpguide.org/mental/obsessive_compulsive_disorder OCD.htm , accessed September 19, 2007.	
	C6	Journal of Clinical Psychiatry, 1999, 60, 1-8.	
	C7	Crow, S. Expert Opinion on Investigational Drugs, 1997, 6(4), 427-36.	
	C8	Ross et al., Expert Opinion on Therapeutic Patents, 2003, 13(10), 1491-99.	
	C9	TAKEHITO OCHI ET AL.: "FR143166 ATTENUATES SPINAL PAIN TRANSMISSION THROUGH ACTIVATION OF THE SEROTONIN SYSTEM" EUROPEAN JOURNAL OF PHARMACOLOGY, Bd. 452, 2002, Pages 319-324, XP002284473, The Entire Document.	
	C10	YOSHIKO SUZUKI ET AL: "IN VITRO AND IN VIVO PHARMACOLOGICAL PROFILE OF 4-(4-FLUOROBENZYLIDENE)-1-{2-[5-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]ETHYL} PIPERIDINE (NRA0161)" LIFE SCIENCES, Bd. 71, 2002, pages 2603-2615, XP002284474, The Entire Document.	
	C11	KATRITZKY ET AL: "1,3-DIPOLAR CYCLOADDITIONS OF ELECTRON-RICH BENZOTRIAZOL-1-YLPROPENES" J. HETEROCYCLIC CHEM., Bd. 33, 1996, Pages 1637-1646, XP002284475, Figure 28, Pages. 1640.	
	C12	PEREZ ET AL: "AN EASY METHOD FOR THE N-ALKYLATION OF AMIDES, CARBAMATES, UREAS AND AZOLES..." HETEROCYCLES, Bd. 60, Nr. 1, 25 November 2002, Pages 167-175, XP002284476, Figures 10,11 and 12, Pages 168 and 173.	

Examiner Signature	/Christopher Stone/	Date Considered	05/27/2009
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/552,065
				Filing Date	October 5, 2005
				First Named Inventor	Kai SCHIEMANN et al.
				Group Art Unit	1614
				Examiner Name	Christopher R. Stone
				Attorney Docket Number	MERCK-3074
Sheet	4	of	4		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C13	O'BRIAN ET AL: "SOME REACTIONS OF 3-HYDROXY-1-PHENYLPYRAZOLE" J. ORG. CHEM., Bd.31, 1966, Pages 1538-1542, XP002284477, The Entire Document.		
	C14	DATABASE CHEMABS 'ONLINE! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1960, GRANDBERG, I.I. ET AL: "PYRAZOLES. XII. HYDROXY-AND CHLOROMETHYLATION OF 1-SUBSTITUTED PYRAZOLES" XP002284480, FOUND IN STN, DATABASE ACCESSION NO. 1961:99421, SUMMARY & ZHURNAL OBSHCHEI KHIMII, 30, 3324-8; CODEN: ZOKHA4; ISSN: 0044-460X, 1960.		
	C15	DATABASE BEILSTEIN; BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 29 NOVEMBER 1988; XP002284481, DATABASE ACCESSION NO. BRN 1127514 CAS-RN; 35000-58-9/ SUMMARY & DORN ET AL: J. PRAKT. CHEM., Bd. 313, 1971, Pages 236-246.		
	C16	BEBERNITZ ET AL.: "THE EFFECT OF 1,3-DIARYL-'1H-PYRAZOL-4-ACETAMIDES ON GLUCOSE UTILIZATION IN OB/OB MICE" J. MED. CHEM., Bd. 44, Nr. 16, 2001, PAGES 2601-2611, XP002284478; SCHEMA 1, METHODE A, STRUKTUREN 2-5, REAKTIONEN A AND B.		
	C17	ECHEVARRIA ET AL: RESEARCH IN THE AZOLE SERIES. 102 '1. SYNTHESIS AND 13C NMR STUDY OF PYRAZOLE-4-CARBOXALDEHYDES: J. HETEROCYCLIC CHEM., Bd. 30, 1993, PAGES 957-960, XP002284479, FORMULA 19, PAGE 957.		
	C18	DATABASE BEILSTEIN, BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 24 JANUARY 2002, XP002284482, DATABASE ACCESSION NO. BRN 8913586 & BRATENKO ET AL: RUSS. J. ORG. CHEM. EN, Bd. 37, Nr. 4, 2001, PAGES 552-555.		
	C19	Caramella, et al., Heterocycles, Vol. 40, No. 2, 1995, pgs 515-520.		
	C20	Katritzky et al., Journal of Heterocyclic Chemistry (1996), 33(6), pgs. 1637-1646.		

Examiner Signature	/Christopher Stone/	Date Considered	05/27/2009
-----------------------	---------------------	--------------------	------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./